Biodesix, Inc. Investigation - BDSX

Company
Biodesix, Inc. (NASDAQ: BDSX)

Learn more about the Biodesix, Inc. Investigation

Required Field

Required Field

Required Field

  • $1 - $1,000
  • $1001 - $10,000
  • $10,001 - $25,000
  • $25,001 - $50,000
  • $50,001 - $100,000
  • $100,001 - $250,000
  • $250,001 - $500,000
  • $500,000+

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Biodesix, Inc. Investigation Details

Biodesix, Inc. shares fell $11.31 per share, or 57.01%, to close at $8.53 on November 6, 2026, after the Company released its third quarter 2026 results. For the quarter, Biodesix reported revenue of $24 million, which came in $3.49 million below consensus estimates. The Company also lowered its revenue outlook for full-year 2026 from a prior range of $108 million to $114 million down to a new range of $101 million to $103 million. In explaining the shortfall in growth, the Company pointed in part to difficulties with its sales organization, including staffing problems. The third quarter results and the reduced outlook were disclosed on November 5, 2026, and the share price decline followed on the next trading day. The size of the single-session decline left shareholders who purchased at higher prices with substantial losses. The investigation concerns whether Biodesix adequately disclosed the condition of its sales force, including staffing challenges, and the resulting effect on revenue growth and its full-year 2026 revenue outlook ahead of the November 5, 2026 third quarter results announcement.

Get Started